Home › Funds › Palo Alto Investors LP › CYTK
Palo Alto Investors LP position in CYTK
CYTOKINETICS INC · Health Care
Palo Alto Investors LP reported holding 30,036 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$2.0M, representing 0.29% of its reported portfolio and ranking #41 among its reported holdings. Palo Alto Investors LP has disclosed CYTK holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Palo Alto Investors LP's CYTK position evolved
Palo Alto Investors LP first disclosed a stake in CYTK in Q3 2023 at 111,717 shares (US$3.3M). The position peaked in Q4 2023 at 111,717 shares, worth US$9.3M. Across 7 filings, Palo Alto Investors LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 30,036 shares valued at US$2.0M — a reduction of -2,159 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 111.72K | $3.29M | New |
| Q4 2023 | 111.72K | $9.33M | Hold |
| Q1 2024 | 111.72K | $7.83M | Hold |
| Q2 2024 | 111.72K | $6.05M | Hold |
| Q1 2026 | 32.20K | $2.12M | New |
| Q2 2026 | 32.20K | $2.74M | Hold |
| Q3 2026 | 30.04K | $1.98M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (CYTOKINETICS INC) is a Health Care company. 36 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.25B), Avoro Capital Advisors LLC (US$323.0M), Polar Capital Holdings Plc (US$227.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.91M sh · $1.25B · Q3 2026
- Avoro Capital Advisors LLC 4.90M sh · $322.96M · Q3 2026
- Polar Capital Holdings Plc 9.64M sh · $227.69M · Q3 2026
- RTW INVESTMENTS, LP 2.86M sh · $188.63M · Q3 2026
- ARMISTICE CAPITAL, LLC 1.18M sh · $77.79M · Q3 2026
- Integral Health Asset Management, LLC 1.60M sh · $72.50M · Q3 2026
- GW&K Investment Management, LLC 1.02M sh · $67.08M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $64.62M · Q3 2026
- Melqart Asset Management (UK) Ltd 761.54K sh · $50.19M · Q3 2026
- Affinity Asset Advisors, LLC 750.00K sh · $49.43M · Q3 2026
- Foresite Capital Management IV, LLC 714.70K sh · $47.11M · Q3 2026
More on Palo Alto Investors LP
FAQ
How long has Palo Alto Investors LP held CYTK?
Palo Alto Investors LP has disclosed CYTK holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
What is Palo Alto Investors LP's current position in CYTK?
As of Q3 2026, Palo Alto Investors LP holds 30.04K shares of CYTK (CYTOKINETICS INC), valued at $1.98M, representing 0.29% of its reported portfolio and ranking #41.
Has Palo Alto Investors LP been buying or selling CYTK?
In the latest 13F filing (Q3 2026), Palo Alto Investors LP reduced its position in CYTK. The position peaked in Q4 2023 at 111.72K shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, Polar Capital Holdings Plc, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.